Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…
Denmark Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+ growth strategy and response to rising allergy prevalence, unique “field to pharmacy” production model, and ambitions to balance strong European…
Switzerland Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition. From navigating a near-collapse to redefining the company’s role…
Saudi Arabia Cooper Pharma, with its 90-year legacy, is at the forefront of transforming the pharmaceutical landscape in the Middle East. From localizing production in Saudi Arabia to pioneering collaborations with global institutions, the company is driving innovation in a rapidly evolving market. As Saudi Arabia’s Vision 2030 reshapes the future of…
Switzerland This interview explores the transformative journey of Tillotts Pharma under the leadership of CEO Thomas Tóth von Kiskér, who has guided the company from a small team in 1996 to a global player with a focus on in-house R&D, strategic M&A, and a commitment to patient-centric innovation. Priorities for continued…
India Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.” DeYoung also touches on what brought him from the world of consulting and private equity to a family-owned Indian pharma…
Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…
Italy Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of Angelini’s USD 960 million Arvelle acquisition, why he is optimistic about success in the challenging brain health space, and how…
Spain Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The Italian executive reflects on his first few months at the helm, the cumulative experience of Almirall’s management board, the global…
Spain Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree shift that entailed the divestment of its generics portfolio, new affiliates across the world, and a more focused product pipeline.…
Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…
Denmark Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years, LEO is now on the lookout for a replacement with capital market experience and the ability to steer the firm…
See our Cookie Privacy Policy Here
